National precision medicine cancer trial
During the end of 2023, representatives from the PCM program began to participate in the planning of a national Swedish cancer trial using precision medicine. A prospective, non-randomized, clinical trial evaluating the efficacy of commercially available anti-cancer drugs for patients with advanced cancer and diagnosed with potentially actionable alterations revealed by genomic testing.
The work was initiated within the network of “Testbed Sweden for Clinical Trials and Implementation of Precision Health in Cancer Care”, Test Bed Sweden for Precision Health in Cancer – Nollvision Cancer .